Skip to main content
NCBI home page
Saudi Journal of Biological Sciences logoLink to Saudi Journal of Biological Sciences
. 2018 Aug 22;26(1):160–164. doi: 10.1016/j.sjbs.2018.08.020

Interfering PLD1-PED/PEA15 interaction using self-inhibitory peptides: An in silico study to discover novel therapeutic candidates against type 2 diabetes

Mohammad Hassan Baig a,⁎, Mohd Adnan Kausar b, Fohad Mabood Husain c, Shazi Shakil d,e,f, Irfan Ahmad g,j, Brijesh S Yadav h, Mohd Saeed i
PMCID: PMC6319087  PMID: 30622421

Abstract

Diabetes type 2 (T2D) is a very complex disorder with a large number of cases reported worldwide. There are several reported molecular targets which are being used towards drug design. In spite of extensive research efforts, there is no sure shot treatment available. One of the major reasons for this failure or restricted success in T2D research is the identification of a major/breakthrough therapeutic target responsible for the progression of T2D. It has been well documented that one of the major causes mediating the insulin resistance is the interaction of PLD1 with PED/PEA15. Herein, we have performed in silico experiments to investigate the interaction between PLD1 with PED/PEA15. Furthermore, this study has explored pertinent molecular interactions involving the self-derived peptides. The peptides identified in this study are found to be capable of restricting the interaction of these two proteins. Accordingly, the study suggests that the “self-derived peptides” could be used as promising therapeutic candidate(s) against T2D.

Keywords: Diabetes, Phospholipase D1 (PLD1), Phosphoprotein enriched in diabetes (PED/PEA15), Molecular interactions, Peptides

1. Introduction

Diabetes type 2 (T2D) is a complex disorder, which is usually diagnosed by the features of hyperglycaemia, commonly affects by defects in the secretion and action of insulin (Kaneto et al., 2016, American Diabetes, 2009, Olokoba et al., 2012). Recent findings gives an impression that the environmental determinants on the human genome are very much responsible for current scenario of wide spread epidemics cases of T2D (Fiory et al., 2017, Prasad and Groop, 2015, Sears and Genuis, 2012, Tabish, 2007). However, the identification of most important therapeutic target genes mainly responsible for the progression of this disorder is still a quest (Stancakova and Laakso, 2016, Kwak and Park, 2016). Condorelli et al. conducted experimentations on skin fibroblast mRNAs from the T2D individuals and they adopted a differential display approach to identify the differentially expressed genes in T2D (Condorelli et al., 1998). They reported a 15 KDa protein which was found to be highly expressed in the skin fibroblasts of T2D individuals, along with the expression level of this protein was also high in the adipose tissues and the skeletal muscle of the T2D subjects (Condorelli et al., 1998). Later the cloning was performed and the identified 15 KDa protein was termed PED/PEA-15 (Araujo et al., 1993). Later several studies were conducted on this protein and reports suggest that this 15 KDa cytoplasmic protein is ubiquitously expressed in human tissues and is found to be highly conserved among species. It was found that PED/PEA-15 demonstrates no catalytic activity but it rather serves as a molecular adaptor playing crucial role in regulating several intracellular functions (Fiory et al., 2017). Despite being a small 15 KDa protein, PEA-15 also serves as a major modulator of apoptosis, proliferation, nutrient metabolism and survival in different cell types (Fiory et al., 2009, Condorelli et al., 1999, Renault et al., 2003, Renganathan et al., 2005, Vigliotta et al., 2004).

There are several reports highlighting the overexpression of PED/PEA15 in several tissues of type 2 diabetes affected individuals (Valentino et al., 2006, Viparelli et al., 2008). Finding also suggests that in intact cells and transgenic animal models, the overexpression of PEA15 impairs insulin regulation of glucose transport by a mechanism mediated by the interaction of PEA15 with the D4 region of Phospholipase D1 (PLD1) which consequently results in the increase of protein kinase C-α activity (Fiory et al., 2017, Viparelli et al., 2008).

PLDs are another ubiquitously expressed enzyme which are widely distributed in animals, bacteria, fungi, and plants and catalyzes the formation of phosphatidic acid (PA), which is an an intracellular messenger implicated in various cellular processes (Huang and Frohman, 2009, Doti et al., 2010). PA is further converted into several other mediators, one of them is diacylglycerol (DAG), which is a major activator of phosphokinase C isoforms (PKCs) (Cummings et al., 2002).

The activity of PLD1 is found to be synergistically regulated by small GTPases, and one of them are isoforms of protein kinase C (PKC) mainly PKC-α (Sung et al., 1997, Powner and Wakelam, 2002, Exton, 2002). The increased activity of PLD1 is reported to be negatively regulating the glucose transport by a mechanism involving its interaction with PED/PEA15 (Condorelli et al., 1998, Valentino et al., 2006). As mentioned earlier, PEA15 is found to be overexpressed in in individuals affected by type 2 diabetes. A molecular mechanism has been proposed earlier, where the insulin resistance is mediated by the interaction of PLD1 with PED/PEA15 (Vigliotta et al., 2004, Zhang et al., 2000). Studies also reported that the blocking this PLD1-PED/PEA15 interaction with either the D4 region of PLD1 or with the peptide derive from the D4 region of PLD-1 or from PED/PEA15 results in the re-establishment of normal PKC signaling and the glucose uptake, which could be a useful way to encounter the progression of T2D (Fig. 1) (Fiory et al., 2017, Viparelli et al., 2008, Zhang et al., 2000, Viparelli et al., 2008).

Fig. 1.

Fig. 1

Open in a new tab

Mechanism involve in PLD1-PED/PEA15 interaction and Type2 Diabetes progression.

Adapted from Fiory et al. (2017).

Here in this study we have explore the interaction of PLD-1 with PED/PEA15 using in silico protein-protein interaction approach. Further we derived the self-inhibitory peptides from PLD-1 and PED/PEA15 proteins and these linear peptide segments were found to be maximum contributing in the PLD1-PED/PEA15 interaction. So we assume these peptides could be used as a inhibitory peptides capable of blocking the PLD1-PED/PEA15 interaction. These peptides are suggested to be used as an important segment for future studies aimed at developing novel compounds with great therapeutic potential in T2D.

2. Material and methods

2.1. Structure modelling

The crystal structure of PED/PEA15 as available with protein databank (pdb id: 4iz5) (Mace et al., 2013), while the structure of PLD-1 was unavailable. Here we modelled the 3D protein structure of D4 region of PLD-1. The complete amino acid sequence of PLD-1 was retrieved from uniprot database (Apweiler et al., 2004) and the amino acids of the D4region were selected for structural modelling purpose (residues 712–1024). I-tasser program (Zhang, 2008) was used to model the structure of PLD-1 (D4 Region). Five structures were generated by I-tasser. All the structures were refined using 3Drefine server (Bhattacharya et al., 2016). Further the structures were validated using Rampage and the structure passing the steriochemical properties check was used in this study (http://mordred.bioc.cam.ac.uk/~rapper/rampage.php).

2.2. Protein-Protein interaction study:

The structure of PED/PEA15 and PLD1 were subjected to protein-protein interaction study using patch dock (Schneidman-Duhovny et al., 2005). The results obtained from patchdock were further refined using firedock algorithm (Andrusier et al., 2007).

2.3. Deriving self-inhibitory peptides:

The peptiderive server was used to derive self-inhibitory peptides (Sedan et al., 2016). Here the PED/PEA15-PLD1 complex was uploaded in the peptiderive server and the self-inhibitory peptides were derived from the PLD1 and PED/PEA15 protein of the complex. Here the peptides derived are the linear peptide segments from each protein highly contributing to its interaction with another protein. Peptide of different length ranging from 5 to 25 amino acids was derived in this step. All the peptides were evaluated on the basis of the interface scores. The top most contributory peptides from each protein were selected.

3. Results and discussion

Due to the unavailability of the 3D structure of PLD-1, here we modelled the structure of PLD-1 using its amino acid sequence information. It is widely reported that the D4 region of PLD-1 is majorly involved in its interaction with PED/PEA15, suggesting that PED/PEA15 impairs insulin regulation of glucose transport, and this process is mediated by a mechanism involving its interaction with the D4 region of PLD-1 (Viparelli et al., 2008, Doti et al., 2010, Viparelli et al., 2008). Taking these information into account, here we modelled the structure of D4 region using the in silico approach. The program I-tasser was used for modelling the structure of PLD-1 (Yang et al., 2015). The structure generated by I-tasser was further refined using 3Drefine server (Bhattacharya et al., 2016). For efficient protein structure refinement, this server utilizes two-step process involving the iterative optimization of hydrogen bonding network combined with atomic-level energy minimization on the optimized model using a composite physics and knowledge-based force fields (Bhattacharya et al., 2016). Further the stereochemistry quality of the modeled structure was validated using RAMPAGE. The Ramachandran plot generated by RAMPAGE (Lovell et al., 2003) reveals that a large proportion of amino acid residues of the modeled structure we present in the in most favored region (93.3%), while just 1% residues were present in the outlier region. It is well evident that interfering the PED/PEA-15- PLD1 interaction restores insulin sensitivity (Viparelli et al., 2008).

Protein-protein interaction study was carried out using patchdock to get an insight into the interaction of PED/PEA15 with PLD1. The complex generated by patch dock were further refined using firedock for 1000 steps and the complex with the best global energy score was selected for further investigation. Here we found that PED/PEA15 interacts with PLD-1 with global free energy score of −71.69 (Fig. 2). Later, the PED/PEA15 -PLD1 complex was investigated using peptiderive server which predicts the interfacing linear peptides from both PLD1 and PED/PEA15 which contribute most to the interaction of these two proteins. Here our approach was to find out the fragments constituting a large portion of the binding energy, these selected fragments were further selected and can be considered to be candidates used for competing with the existing PED/PEA15-PLD1 interaction. The peptide ranging from 5 to 25 residues in each protein along with their contribution in complex formation was analyzed. The peptide found to be showing significant binding energy is reported. The interface score corresponds to the binding energy of the protein-peptide/protein-protein complex. In our study, the total interface score for PLD1- PED/PEA15 complex was found to be -13.634. While the peptides spanning residues [782–805] and [782–806] were showing maximum contribution in the binding of PED/PEA15 with PLD1, where these peptide binds with the interface score of −7.389 and −7.382 respectively. This suggests that these two peptides were contributing 54.20% and 54.15% of the total interface score of PLD1- PED/PEA15 complex (Table 1). These selected hot segments derived from the peptiderive tool could compete with their originally derived proteins (PLD1 or PED/PEA15) from for binding to the partner. Suggesting these short 23 mers and 24 mers PLD1 mimicking peptides can be used as effective antagonists capable of disrupting the PLD1-PED/PEA15 interaction. In the previous studies it has been well reported that the synthetic peptides derived from the spanning residues 762–801 of PLD-1 act as a potent binding competitors (Doti et al., 2010). Our finding are also very much in harmony with the previous results reported by different research groups. Likewise another group of linear peptides were derived from PED/PEA15 protein. It was earlier reported that the linear segment of PED/PEA15 comprising of residues 1–24 abrogates the formation of PED/PEA15-PLD1 complex and subsequently reducing the activity of protein kinase C-α (Viparelli et al., 2008). An important finding in this study was that the administration of this peptide successfully restores the insulin-stimulated glucose uptake (upto 70%). In our study we found that PED-(1-19) was the most actively participating segment and this peptide was found to show interface score of -11.610, followed by PED/PEA15 -(1-20), (1-21), (1-23), (1-24) and (1-25) (Table 2). The selected peptides were further tested to confirm their accuracy. The selected peptides in complex with their respective receptor protein were subjected to dock against another partner protein and the binding affinity was compared. For instance the topmost scoring peptide derived from PED/PEA15 (1–19) in complex with PDL-1 was subjected to interact with PED. It was found that in the presence in PED/PEA15 derived peptide PLD-1 interacts with PED with global free energy score of −61.66 (Fig. 3), suggesting that the PED/PEA15 derive peptide was restricting the interaction of PLD-1 with PED/PEA15. Likewise in the presence of PED/PEA15 (1–20) peptide, the global free energy score was reduced to −52.25. In Table 3 we have listed the binding sores of PED/PEA15-PLD-1 complex in the presence and absence of derived peptides. This in silico analysis provides a clue that the use of PED/PEA15 (1–19) segment will be a better and effective mimics and will be a more active competitor restricting the interaction of PED/PEA15 to PLD-1.

Fig. 2.

Fig. 2

Open in a new tab

Interaction of PED/PEA15 with PLD1 and the residues involved in their binding.

Table 1.

The linear peptides derived from PLD-1 and their Interface score and other details.

Peptide length Interface score Relative interface score (%) Sequence
5 −4.192 30.74 AEYGT
6 −5.046 37.01 YGTLLQ
7 −5.435 39.86 EYGTLLQ
8 −6.224 45.65 AEYGTLLQ
9 −6.928 50.81 MAEYGTLLQ
10 −6.823 50.04 MAEYGTLLQD
11 −6.881 50.47 MAEYGTLLQDL
12 −6.889 50.53 MAEYGTLLQDLT
13 −7.701 56.48 GTLLQDLTNNITL
14 −9.148 67.09 YGTLLQDLTNNITL
15 −9.537 69.95 EYGTLLQDLTNNITL
16 −10.327 75.74 AEYGTLLQDLTNNITL
17 −11.03 80.9 MAEYGTLLQDLTNNITL
18 −11.024 80.85 MAEYGTLLQDLTNNITLE
19 −11.61 85.15 MAEYGTLLQDLTNNITLED
20 −11.601 85.09 MAEYGTLLQDLTNNITLEDL
21 −11.601 85.09 MAEYGTLLQDLTNNITLEDLE
22 −11.601 85.09 MAEYGTLLQDLTNNITLEDLEQ
23 −11.601 85.09 MAEYGTLLQDLTNNITLEDLEQL
24 −11.601 85.09 MAEYGTLLQDLTNNITLEDLEQLK
25 −11.601 85.09 MAEYGTLLQDLTNNITLEDLEQLKS
Open in a new tab

Table 2.

The linear peptides derived from PED/PEA15 and their Interface score and other details.

Peptide length Interface score Relative interface score (%) Sequence
5 −2.946 21.61 FFISC
6 −5.162 37.86 QKYRVY
7 −5.162 37.86 NQKYRVY
8 −5.175 37.96 ENQKYRVY
9 −5.175 37.96 RENQKYRVY
10 −5.428 39.81 HRENQKYRVY
11 −5.545 40.67 AHRENQKYRVY
12 −5.873 43.08 FFISCADDKVVF
13 −6.592 48.35 QFFISCADDKVVF
14 −6.592 48.35 QFFISCADDKVVFN
15 −6.369 46.71 RILKAHRENQKYRVY
16 −6.369 46.71 QRILKAHRENQKYRVY
17 −6.725 49.32 QFFISCADDKVVFNKIG
18 −6.725 49.32 QFFISCADDKVVFNKIGD
19 −6.725 49.32 QFFISCADDKVVFNKIGDA
20 −6.725 49.32 QFFISCADDKVVFNKIGDAI
21 −6.734 49.39 QFFISCADDKVVFNKIGDAIA
22 −6.923 50.78 IGDAIAQRILKAHRENQKYRVY
23 −6.733 49.38 QFFISCADDKVVFNKIGDAIAQR
24 −7.389 54.2 QFFISCADDKVVFNKIGDAIAQRI
25 −7.382 54.15 QFFISCADDKVVFNKIGDAIAQRIL
Open in a new tab

Fig. 3.

Fig. 3

Open in a new tab

Interaction of PED/PEA15 with PLD1 in complex with their self-derive inhibitors. (a) Interaction of PED/PEA15 with PLD1 (b) Interaction of PED/PEA15 with PLD1in presence of PLD-1 derived peptide (c) Interaction of PED/PEA15 with PLD1in presence of PED/PEA15 derived peptide.

Table 3.

Global energy score of PLD1-PED in presence and absence of self-inhibitory peptides.

Complex Global Energy
PLD1-PED −71.69
PLD1-PED/PEA15 (in complex with PED/PEA15 [1–19] derive peptide) −61.66
PLD1-PED/PEA15 (in complex with PED/PEA15 [1–20] derive peptide) −52.25
PLD1-PED/PEA15 (in complex with PLD [782–805] derive peptide) −55.81
PLD1-PED/PEA15 (in complex with PLD [782–806] derive peptide) −59.01
Open in a new tab

4. Conclusion

It has been well established that interrupting the PLD1-PED/PEA15 interaction is one of the important target for type 2 diabetes. Here in this study we have screened out some of the linear peptide segments from PLD-1 and PED/PEA15 which are majorly contributing to their interaction. The peptide may act as a competitive inhibitor interrupting the PLD1-PED/PEA15 interaction resulting in the restoration of insulin-stimulated glucose uptake.

Acknowledgement

This work was supported by the National Research Foundation, Korea under grant funded by the Korea government (MSIT) (No. NRF-2018R1C1B5047470).

Footnotes

Peer review under responsibility of King Saud University.

References

  1. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabet. Care. 2009;32(Suppl 1):S62–S67. doi: 10.2337/dc09-S062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andrusier N., Nussinov R., Wolfson H.J. FireDock: fast interaction refinement in molecular docking. Proteins. 2007;69(1):139–159. doi: 10.1002/prot.21495. [DOI] [PubMed] [Google Scholar]
  3. Apweiler R., Bairoch A., Wu C.H., Barker W.C., Boeckmann B., Ferro S., Gasteiger E., Huang H., Lopez R., Magrane M., Martin M.J., Natale D.A., O'Donovan C., Redaschi N., Yeh L.S. UniProt: the Universal Protein knowledgebase. Nucl. Acids Res. 2004;32(Database issue):D115–D119. doi: 10.1093/nar/gkh131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Araujo H., Danziger N., Cordier J., Glowinski J., Chneiweiss H. Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J. Biol. Chem. 1993;268(8):5911–5920. [PubMed] [Google Scholar]
  5. Bhattacharya D., Nowotny J., Cao R., Cheng J. 3Drefine: an interactive web server for efficient protein structure refinement. Nucl. Acids Res. 2016;44(W1):W406–W409. doi: 10.1093/nar/gkw336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Condorelli G., Vigliotta G., Iavarone C., Caruso M., Tocchetti C.G., Andreozzi F., Cafieri A., Tecce M.F., Formisano P., Beguinot L., Beguinot F. PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J. 1998;17(14):3858–3866. doi: 10.1093/emboj/17.14.3858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Condorelli G., Vigliotta G., Cafieri A., Trencia A., Andalo P., Oriente F., Miele C., Caruso M., Formisano P., Beguinot F. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene. 1999;18(31):4409–4415. doi: 10.1038/sj.onc.1202831. [DOI] [PubMed] [Google Scholar]
  8. Cummings R., Parinandi N., Wang L., Usatyuk P., Natarajan V. Phospholipase D/phosphatidic acid signal transduction: role and physiological significance in lung. Mol. Cell Biochem. 2002;234–235(1–2):99–109. [PubMed] [Google Scholar]
  9. Doti N., Cassese A., Marasco D., Paturzo F., Sabatella M., Viparelli F., Dathan N., Monti S.M., Miele C., Formisano P., Beguinot F., Ruvo M. Residues 762–801 of PLD1 mediate the interaction with PED/PEA15. Mol. Biosyst. 2010;6(10):2039–2048. doi: 10.1039/c005272h. [DOI] [PubMed] [Google Scholar]
  10. Exton J.H. Regulation of phospholipase D. FEBS Lett. 2002;531(1):58–61. doi: 10.1016/s0014-5793(02)03405-1. [DOI] [PubMed] [Google Scholar]
  11. Fiory F., Formisano P., Perruolo G., Beguinot F. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 2009;297(3):E592–E601. doi: 10.1152/ajpendo.00228.2009. [DOI] [PubMed] [Google Scholar]
  12. Fiory F., Spinelli R., Raciti G.A., Parrillo L., D'Esposito V., Formisano P., Miele C., Beguinot F. Targetting PED/PEA-15 for diabetes treatment. Expert Opin. Ther. Targets. 2017;21(6):571–581. doi: 10.1080/14728222.2017.1317749. [DOI] [PubMed] [Google Scholar]
  13. Huang H., Frohman M.A. Lipid signaling on the mitochondrial surface. Biochim. Biophys. Acta. 2009;1791(9):839–844. doi: 10.1016/j.bbalip.2009.05.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kaneto H., Matsuoka T.A., Kimura T., Obata A., Shimoda M., Kamei S., Mune T., Kaku K. Appropriate therapy for type 2 diabetes mellitus in view of pancreatic beta-cell glucose toxicity: “the earlier, the better”. J. Diabet. 2016;8(2):183–189. doi: 10.1111/1753-0407.12331. [DOI] [PubMed] [Google Scholar]
  15. Kwak S.H., Park K.S. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp. Mol. Med. 2016;48:e220. doi: 10.1038/emm.2016.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lovell S.C., Davis I.W., Arendall W.B., 3rd, de Bakker P.I., Word J.M., Prisant M.G., Richardson J.S., Richardson D.C. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins. 2003;50(3):437–450. doi: 10.1002/prot.10286. [DOI] [PubMed] [Google Scholar]
  17. Mace P.D., Wallez Y., Egger M.F., Dobaczewska M.K., Robinson H., Pasquale E.B., Riedl S.J. Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK. Nat. Commun. 2013;4:1681. doi: 10.1038/ncomms2687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Olokoba A.B., Obateru O.A., Olokoba L.B. Type 2 diabetes mellitus: a review of current trends. Oman. Med. J. 2012;27(4):269–273. doi: 10.5001/omj.2012.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Powner D.J., Wakelam M.J. The regulation of phospholipase D by inositol phospholipids and small GTPases. FEBS Lett. 2002;531(1):62–64. doi: 10.1016/s0014-5793(02)03410-5. [DOI] [PubMed] [Google Scholar]
  20. Prasad R.B., Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes. (Basel) 2015;6(1):87–123. doi: 10.3390/genes6010087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Renault F., Formstecher E., Callebaut I., Junier M.P., Chneiweiss H. The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes. Biochem. Pharmacol. 2003;66(8):1581–1588. doi: 10.1016/s0006-2952(03)00514-8. [DOI] [PubMed] [Google Scholar]
  22. Renganathan H., Vaidyanathan H., Knapinska A., Ramos J.W. Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD. Biochem. J. 2005;390(Pt 3):729–735. doi: 10.1042/BJ20050378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schneidman-Duhovny D., Inbar Y., Nussinov R., Wolfson H.J. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucl. Acids Res. 2005;33(Web Server issue):W363–W367. doi: 10.1093/nar/gki481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sears M.E., Genuis S.J. Environmental determinants of chronic disease and medical approaches: recognition, avoidance, supportive therapy, and detoxification. J. Environ. Publ. Health. 2012;2012 doi: 10.1155/2012/356798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sedan Y., Marcu O., Lyskov S., Schueler-Furman O. Peptiderive server: derive peptide inhibitors from protein-protein interactions. Nucl. Acids Res. 2016;44(W1):W536–W541. doi: 10.1093/nar/gkw385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stancakova A., Laakso M. Genetics of type 2 diabetes. Endocr. Dev. 2016;31:203–220. doi: 10.1159/000439418. [DOI] [PubMed] [Google Scholar]
  27. Sung T.C., Roper R.L., Zhang Y., Rudge S.A., Temel R., Hammond S.M., Morris A.J., Moss B., Engebrecht J., Frohman M.A. Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity. EMBO J. 1997;16(15):4519–4530. doi: 10.1093/emboj/16.15.4519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tabish S.A. Is diabetes becoming the biggest epidemic of the twenty-first century? Int. J. Health Sci. (Qassim) 2007;1(2):V–VIII. [PMC free article] [PubMed] [Google Scholar]
  29. Valentino R., Lupoli G.A., Raciti G.A., Oriente F., Farinaro E., Della Valle E., Salomone M., Riccardi G., Vaccaro O., Donnarumma G., Sesti G., Hribal M.L., Cardellini M., Miele C., Formisano P., Beguinot F. The PEA15 gene is overexpressed and related to insulin resistance in healthy first-degree relatives of patients with type 2 diabetes. Diabetologia. 2006;49(12):3058–3066. doi: 10.1007/s00125-006-0455-5. [DOI] [PubMed] [Google Scholar]
  30. Vigliotta G., Miele C., Santopietro S., Portella G., Perfetti A., Maitan M.A., Cassese A., Oriente F., Trencia A., Fiory F., Romano C., Tiveron C., Tatangelo L., Troncone G., Formisano P., Beguinot F. Overexpression of the ped/pea-15 gene causes diabetes by impairing glucose-stimulated insulin secretion in addition to insulin action. Mol. Cell Biol. 2004;24(11):5005–5015. doi: 10.1128/MCB.24.11.5005-5015.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Viparelli F., Cassese A., Doti N., Paturzo F., Marasco D., Dathan N.A., Monti S.M., Basile G., Ungaro P., Sabatella M., Miele C., Teperino R., Consiglio E., Pedone C., Beguinot F., Formisano P., Ruvo M. Targeting of PED/PEA-15 molecular interaction with phospholipase D1 enhances insulin sensitivity in skeletal muscle cells. J. Biol. Chem. 2008;283(31):21769–21778. doi: 10.1074/jbc.M803771200. [DOI] [PubMed] [Google Scholar]
  32. Viparelli F., Doti N., Sandomenico A., Marasco D., Dathan N.A., Miele C., Beguinot F., Monti S.M., Ruvo M. Expression and purification of the D4 region of PLD1 and characterization of its interaction with PED-PEA15. Protein Expr. Purif. 2008;59(2):302–308. doi: 10.1016/j.pep.2008.02.012. [DOI] [PubMed] [Google Scholar]
  33. Yang J., Yan R., Roy A., Xu D., Poisson J., Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat. Methods. 2015;12(1):7–8. doi: 10.1038/nmeth.3213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008;9:40. doi: 10.1186/1471-2105-9-40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Zhang Y., Redina O., Altshuller Y.M., Yamazaki M., Ramos J., Chneiweiss H., Kanaho Y., Frohman M.A. Regulation of expression of phospholipase D1 and D2 by PEA-15, a novel protein that interacts with them. J. Biol. Chem. 2000;275(45):35224–35232. doi: 10.1074/jbc.M003329200. [DOI] [PubMed] [Google Scholar]

Articles from Saudi Journal of Biological Sciences are provided here courtesy of Elsevier

RESOURCES